Amphotericin B induced abnormalities in human platelets

K B Pastakia, N E Brownson, D A Terle, B J Poindexter

Abstract

Aims—To investigate in vitro the effect of amphotericin B on platelets in order to understand poor platelet recovery in patients receiving platelet transfusions and amphotericin B simultaneously.

Methods—Washed platelets were isolated from platelet concentrates and exposed to amphotericin B (4 µg/ml) for one hour. Platelet function was assessed by aggregation response to thrombin (0.0–0.6 U/ml), serotonin release, response to hypotonic stress, and mean platelet volume. The expression of surface membrane glycoprotein (GP) Ib-IX complex, GPIIb-IIIa complex and CD62P (P-selectin) was examined by flow cytometry using fluorescence labelled monoclonal antibodies. Heterotypic cell adhesion was measured in amphotericin B treated platelets co-incubated with isolated, autologous polymorphonuclear leucocytes (PMN) by flow cytometric analysis.

Results—Amphotericin B induced platelet dysfunction. The rate of aggregation by thrombin, serotonin uptake and thrombin induced release of serotonin, and the response of platelets to hypotonic stress were inhibited. There was up to a two-fold increase in the mean platelet volume. The expression of platelet surface GPIb-IX and GPIIb-IIIa was not affected. P-selectin, normally expressed only on the surface of activated platelets, was also expressed on unactivated platelets. Amphotericin B increased platelet adherence to PMN and the number of platelets bound per PMN.

Conclusions—In vitro, amphotericin B induces P-selectin expression on the surface of unactivated platelets and increases platelet adhesion to PMN, which is exacerbated by storage. Platelet dysfunction resulting from exposure to amphotericin B may contribute to poor platelet recovery in vivo when amphotericin B is administered concomitantly with platelet transfusion.


Keywords: amphotericin B, platelets, surface membrane glycoprotein, flow cytometry.

Systemic administration of amphotericin B is a standard treatment for mycotic infections. Immunocompromised, critically ill, or patients with cancer often require the simultaneous administration of amphotericin B and blood components. Amphotericin B given concomitantly with platelet transfusion is associated with poor platelet recovery.1,4 The recovery of stored platelets 12–18 hours post-transfusion, relative to fresh platelets, decreased from 89% in clinically stable patients to 65% in patients receiving intravenous amphotericin B.3 In vivo, platelets play a central role in haemostasis by the processes of adhesion and aggregation. Interactions between platelets (haemostatic cells) and inflammatory cells such as polymorphonuclear leucocytes (PMN) are of importance for both haemostasis and inflammation.

Amphotericin B is a lipophilic antibiotic which binds to membrane sterols of mammalian cells, including those in the blood.3,7 This leads to destruction of membrane integrity, increased cell permeability, leakage of cellular contents, and subsequent cell lysis. In vitro, amphotericin B exacerbates a platelet surface membrane lesion, characterised as “pits”,5 and decreases the expression of surface membrane glycoprotein (GP) Ib in stored platelets.9 In the present study we have characterised the in vitro effects of amphotericin B on platelets. Platelet function was assessed by thrombin induced aggregation, serotonin release, hypotonic stress response, and mean platelet volume. The platelet surface is the primary site of exposure to amphotericin B. We have examined the effect of the antibiotic on the surface expression of platelet membrane GPIb-IX complex, GPIIb-IIIa complex and P-selectin and on platelet–PMN adhesion using flow cytometry.

Methods

PLATELET PREPARATION

Platelets were obtained as platelet concentrates by automated plateletpheresis or as platelet rich plasma, from normal human blood collected in 1/11 volume anticoagulant citrate dextrose solution (75 mM trisodium citrate, 38 mM citric acid, 124 mM dextrose) as described previously.10 11 Platelet concentrates were stored in polyolefin bags (Fenwal PL732; Baxter Healthcare Corp., Deerfield, Illinois, USA) on a rotator at room temperature (20–24°C). Incubations in the experiments were carried out at room temperature unless otherwise specified. Washed, unactivated platelets were isolated from platelet concentrates or from platelet rich plasma by centrifugation at 1000 × g for 10 minutes in the presence of 1 µM prostaglandin E1 (PGE1) and resuspen-
sion at a density of $5 \times 10^8$/ml in Tyrode's-HEPES buffer (TH: 137 mM NaCl, 2.7 mM KCl, 0.42 mM NaH$_2$PO$_4$, 12.5 mM NaHCO$_3$, 2.0 mM MgCl$_2$, 5.5 mM D-glucose, 5.0 mM HEPES, and 3.5 mg/ml bovine serum albumin, pH 7.4).

AMPHOTERICIN B TREATMENT
Amphotericin B (Life Technologies, Gaithersburg, Maryland, USA), 250 µg/ml stock solution in saline, was added at a final concentration of 4 µg/ml to the platelet suspension in TH buffer. Platelets were incubated with the antibiotic at 37°C for one hour. An equal volume of saline was added to control samples. The concentration of 4 µg/ml amphotericin B was chosen for study as representative of therapeutic peak concentrations reported with intravenous amphotericin B. In preliminary experiments, thrombin induced platelet aggregation was studied after treatment with 1, 2 and 4 µg/ml amphotericin B and the mean platelet volume was determined after treatment with 1–32 µg/ml amphotericin B.

PLATELET COUNTING AND SIZE ANALYSIS
Platelet counts and size analysis were performed on a System 9000 Hematology Series cell counter (Serono Baker Diagnostics, Allentown, Pennsylvania, USA). The mean platelet volume was used to assess shifts in platelet size.

PLATELET AGGREGATION
Amphotericin B treated platelets and untreated controls (150 µl) were incubated in a microtitre plate with human α-thrombin (lot H2; FDA, Bethesda, Maryland, USA) added at concentrations of 0.18–0.6 U/ml. Aggregation was monitored as a change in the absorbance at 650 nm ($A_{650}$) using a Vmax Kinetic Microplate Reader (Molecular Devices Corporation, Menlo Park, California, USA).

HYPOTONIC STRESS RESPONSE
Platelets (50 µl of 1 ×10$^9$/ml) treated with 4 µg/ml amphotericin B or untreated, control platelets were added to 100 µl TH (buffer controls, −stress) or 100 µl distilled water (+stress). Hypotonic stress response was measured as a change in $A_{650}$ with time using a Vmax Kinetic Microplate Reader.

SEROTONIN UPTAKE AND RELEASE ASSAY
Serotonin release was assayed as described previously. Amphotericin B treated platelets and controls (5 ×10$^8$/ml) were incubated with 0.05 µCi/ml [$^3$H]serotonin (New England Nuclear, Boston, Massachusetts, USA) for 30 minutes at 37°C. Samples were washed once in TH buffer with 1 µM PGE$_1$, and resuspended in TH buffer at 5 ×10$^8$/ml. An aliquot was used to measure the extent of serotonin uptake by scintillation counting. Imipramine (6.8 µM) was added to the final platelet suspension to prevent re-uptake of serotonin following thrombin stimulation. Aliquots (1 ml) were activated by 0.02–4.0 U/ml thrombin for two minutes. Platelets were then fixed by adding 2.5 ml cold 1.5 M formaldehyde and incubation at 4°C for 10 minutes. The platelet suspension was centrifuged at 3200 × g and the serotonin released from platelets was measured in the supernatant. The serotonin release at various thrombin concentrations was expressed as a percent of the total extent of serotonin uptake in the platelets.

PMN ISOLATION
PMN were isolated from autologous human blood as described previously. Briefly, PMN were isolated by dextran sedimentation, density gradient centrifugation using Lymphocyte Separation Medium (Organon Teknika, Durham, North Carolina, USA) and hypotonic lysis of erythrocytes. PMN were washed three times with and resuspended in calcium- and magnesium-free Hank's balanced salt solution (HBSS; Life Technologies) to 10$^7$/ml.

ANTIBODIES
The fluorescein isothiocyanate (FITC) conjugated CD41 monoclonal antibody (clone P2; Immunotech Inc., Westbrook, Maine, USA) recognises an epitope on GPIIb-IIIa complex. The phycoerythrin (PE) conjugated CD62P monoclonal antibody (clone AC1.2; Becton Dickinson Immunocytometry Systems, San Jose, California, USA) recognises the CD62P (P-selectin) antigen, an α-granule membrane protein that is externalised and expressed on the plasma membrane of activated platelets. The GPIb-IX monoclonal antibody (Immunotech Inc.) recognises an epitope only present on the platelet membrane GPIb-IX complex. This monoclonal antibody was labelled with secondary goat anti-mouse IgG-FITC antiserum (Sigma, St Louis, Missouri, USA). All of the monoclonal antibodies are of the IgG class. The isotype control reagents conjugated to either FITC or PE were purchased from Becton Dickinson Immunocytometry Systems.

PREPARATION OF PLATELETS FOR FLOW CYTOMETRY
Labelling of platelets with monoclonal antibodies was carried out as described previously. Amphotericin B treated platelets were diluted to 5 ×10$^8$/ml in TH buffer containing either 5 mM EDTA for assessing monoclonal antibody binding to GPIb-IX or 2 mM CaCl$_2$ (TH-Ca) for binding to GPIb-IIIa and P-selectin. Aliquots (100 µl) were incubated with saturating concentrations of monoclonal antibody. Thrombin (0.032–4.0 U/ml) was added and samples were incubated for 30 minutes. After 15 minutes, a saturating concentration of goat antimouse IgG-FITC secondary antibody was added to samples in which unlabelled GPIb-IX monoclonal antibody was used. The samples were then fixed with an equal volume of 2% formaldehyde in TH buffer for 30 minutes. The samples were diluted to 0.5 ml in TH buffer and analysed using flow cytometry.
Amphotericin B induced abnormalities in human platelets

Platelets were exposed to amphotericin B at 37°C and stimulated with thrombin (0.18 U/ml). Aggregation was measured as changes in light absorption (A650) following addition of thrombin at time 0 minutes.

Results

Platelet Aggregation
Exposure of platelets to TH buffer to increasing amphotericin B concentrations from 1 to 4 µg/ml for one hour at 37°C resulted in a decrease in their A650 (fig 1). Increasing amphotericin B concentrations inhibited the thrombin induced rate of aggregation by 20–70%. The inhibitory effect of amphotericin B was observed at 0.18 U/ml thrombin (fig 1) and similarly at higher thrombin concentrations up to 0.6 U/ml (data not shown). The extent of aggregation was not affected. Examination by light microscopy of untreated platelets and platelets treated with 1–4 µg/ml amphotericin B did not reveal any notable difference in morphology.

Mean Platelet Volume
The effect on mean platelet volume of exposing platelets to TH buffer to varying concentrations of amphotericin B is shown in fig 2. In the presence of 4–32 µg/ml amphotericin B the mean platelet volume increased 1.4–2.6 fold. Platelet count was not affected. Platelets, after five days of storage, showed similar increases in the mean platelet volume on treatment with amphotericin B under the same conditions (data not shown).

Hypotonic Stress Response
Hypotonic stress response was inhibited in platelets exposed to 4 µg/ml amphotericin B, as shown in fig 3. The A50 of amphotericin B treated platelets was lower than the untreated platelets. Under hypotonic stress, the A50 of the untreated platelets decreased initially and then increased, indicating partial recovery. The platelets exposed to antibiotic and subjected to hypotonic stress showed a decrease in A50, which remained unchanged with time.

Serotonin Uptake and Release
Amphotericin B strongly inhibited (85 (5)% total [14C]serotonin uptake, as determined by scintillation counting. Serotonin release in amphotericin B treated platelets is also inhibited upon activation by thrombin (fig 4). The maximum serotonin released, at the highest thrombin concentration (4.0 U/ml), indicated that in control platelets 79 (3)% of total serotonin uptake was releasable, whereas in amphotericin B treated platelets 55 (9)% of total uptake was releasable.
AMPHOTERICIN B

Figure 3  Hypotonic shock response of platelets exposed to amphotericin B. Platelets (50 μl of 1 x 10^7/ml) in TH buffer untreated (–AMB) or treated with 4 μg/ml amphotericin B (+AMB) were added to 100 μl TH buffer (control) or 100 μl distilled water (+stress). Hypotonic stress response was measured as changes in light absorption (A_red) with time. AMB = amphotericin B.

Figure 4  Serotonin release in amphotericin B treated platelets. Thrombin induced serotonin release is illustrated as the per cent of 11C-serotonin loaded into platelets. Control without amphotericin B (AMB) treatment (; platelets treated with 4 μg/ml amphotericin B (•).

SURFACE EXPRESSION OF MEMBRANE GLYCOPROTEINS

Thrombin induced a decrease in surface GPIb-IX expression and an increase in GPIIb-IIIa expression in control and amphotericin B treated platelets (figs 5A and 5B). In fresh, unactivated platelets exposed to amphotericin B surface P-selectin was elevated compared with fresh, control platelets which do not express P-selectin (fig 5C). P-selectin expression was increased by thrombin concentrations of 0.16–4.0 U/ml in both control and amphotericin B treated platelets. Its expression was higher in treated platelets than in untreated ones at low thrombin (0.032 and 0.16 U/ml) concentrations.

The effect of amphotericin B on surface P-selectin expression in stored platelets is shown in fig 6. Surface P-selectin expression was undetectable in fresh platelets but increased with amphotericin B treatment (fig 6A). In five-day stored platelets, surface P-selectin expression was observed in untreated platelets and was significantly increased in amphotericin B treated platelets (fig 6B).

ADHESION OF PLATELETS TO PMN

Isolated platelets and PMN were co-incubated as described. Figure 7 shows the histograms of

Figure 5  Effect of amphotericin B (AMB) on thrombin dependent expression of platelet membrane glycoproteins as determined by flow cytometry. Platelets in TH buffer without amphotericin B (open bars) or with 4 μg/ml amphotericin B (shaded bars) were incubated at 37 °C for one hour. Monoclonal antibodies were added and the platelets stimulated with 0.32–4.0 U/ml thrombin for 30 minutes before fixing. Bar graphs illustrate (A) GPIb-IX, (B) GPIIb-IIIa and (C) CD62P expression as mean channel fluorescence. This experiment is representative of three separate experiments.

a representative assay of the effect of amphotericin B on platelet adhesion to PMN. The platelets were labelled with anti-GPIIb-IIIa-FITC monoclonal antibody. PMN events positive for the platelet marker fluorescence represent PMN with bound platelets. A threshold marker for platelet fluorescence was set using
Amphotericin B induced abnormalities in human platelets

Amphotericin B induced fresh platelets

Figure control suspended exposed threshold

Table experiment

This experiment is representative of three separate experiments.

Discussion

Simultaneous administration of amphotericin B with transfusion of stored platelets induces an impressive decrease in in vivo platelet recovery and survival in myelosuppressed patients. In our in vitro studies we examined the effect of amphotericin B on platelet function and the expression of surface membrane glycoprotein in fresh and stored platelets. Exposure of washed platelets to therapeutic concentrations of amphotericin B (4 μg/ml) for one hour resulted in impaired function in both fresh and stored platelets. The rate of aggregation by thrombin, serotonin uptake and release, and response to hypotonic stress were inhibited, and the mean platelet volume was increased. Amphotericin B binds to steroids of mammalian cell membranes and functions as an ionophore, inducing extensive permeability to ions. Such an effect on the platelet membranes could result in the observed increase in the mean platelet volume on treatment with amphotericin B. The inhibition of serotonin uptake observed by us, could be the result of disruption of the transmembrane proton, Na⁺, and K⁺ gradients which are required for active transport of serotonin across the platelet plasma membrane. Inhibition of serotonin release may be because of its lower uptake on exposure to amphotericin B. Exposure of red blood cells to amphotericin B in vitro causes cell lysis subsequent to disruption of membrane permeability. However, in vivo increased cation pumping by healthy red cells compensates for the damage. Administration of amphotericin B with granulocyte transfusion has been reported to cause lethal pulmonary reactions, possibly from PMN lysis and release of proteases that damage the tissue. A more recent study, however, showed no detrimental interaction between granulocyte transfusion and amphotericin B. Studies of platelets using scanning electron microscopy show a significant increase in "pit" formation in stored platelets exposed to

Table 1 Heterotypic adhesion of platelets to PMN. Results are expressed as mean (SD)

<table>
<thead>
<tr>
<th></th>
<th>PMN binding platelets (%)</th>
<th>Platelet fluorescence ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unactivated</td>
<td>Activated</td>
</tr>
<tr>
<td>Control</td>
<td>52 (11)</td>
<td>99 (1)</td>
</tr>
<tr>
<td>Amphotericin B</td>
<td>83 (10)</td>
<td>89 (10)</td>
</tr>
</tbody>
</table>

an isotype control (figs 7A and B; thin lines); events with fluorescence levels above this threshold represent PMN with bound platelets.

Amphotericin B increased platelet adherence to PMN as shown by the increase in the percentage of PMN which had platelets bound and the number of platelets bound per PMN. In the representative experiment (fig 7), unactivated platelets co-incubated with PMN resulted in 41% of PMN having adhered platelets (fig 7A; dashed line), whereas 73% of PMN bound amphotericin B treated, unactivated platelets (fig 7A; bold line). Thrombin activated platelets, untreated or treated with amphotericin B, were bound by 98% and 80% of PMN, respectively (fig 7B; dashed and bold lines). Exposure of platelets to amphotericin B increased the number of unactivated platelets bound per PMN—that is, the mean platelet fluorescence ratio, from 2 to 9. The mean platelet fluorescence ratios of PMN binding activated platelets without and with amphotericin B were 10 and 9, respectively. The results of three experiments are summarised in table 1. The percentage of PMN binding unactivated platelets was significantly increased by treatment with amphotericin B (p < 0.003). Thrombin activation of untreated and treated platelets also increased the percentage of PMN binding platelets (p < 0.009). The platelet fluorescence ratio increased upon amphotericin B treatment of unactivated platelets (p < 0.004). Thrombin activation of untreated platelets increased the platelet fluorescence ratio (p < 0.02).

Discussion

Simultaneous administration of amphotericin B with transfusion of stored platelets induces an impressive decrease in in vivo platelet recovery and survival in myelosuppressed patients. In our in vitro studies we examined the effect of amphotericin B on platelet function and the expression of surface membrane glycoprotein in fresh and stored platelets. Exposure of washed platelets to therapeutic concentrations of amphotericin B (4 μg/ml) for one hour resulted in impaired function in both fresh and stored platelets. The rate of aggregation by thrombin, serotonin uptake and release, and response to hypotonic stress were inhibited, and the mean platelet volume was increased. Amphotericin B binds to steroids of mammalian cell membranes and functions as an ionophore, inducing extensive permeability to ions. Such an effect on the platelet membranes could result in the observed increase in the mean platelet volume on treatment with amphotericin B. The inhibition of serotonin uptake observed by us, could be the result of disruption of the transmembrane proton, Na⁺, and K⁺ gradients which are required for active transport of serotonin across the platelet plasma membrane. Inhibition of serotonin release may be because of its lower uptake on exposure to amphotericin B. Exposure of red blood cells to amphotericin B in vitro causes cell lysis subsequent to disruption of membrane permeability. However, in vivo increased cation pumping by healthy red cells compensates for the damage. Administration of amphotericin B with granulocyte transfusion has been reported to cause lethal pulmonary reactions, possibly from PMN lysis and release of proteases that damage the tissue. A more recent study, however, showed no detrimental interaction between granulocyte transfusion and amphotericin B. Studies of platelets using scanning electron microscopy show a significant increase in "pit" formation in stored platelets exposed to
expression was increased notably upon amphotericin B treatment compared with amphotericin B treated fresh platelets. P-selectin expression on the platelet surface membrane is a marker of platelet activation and its expression on platelet surface membranes has been shown to correlate with storage and reduced recovery one hour post-transfusion. The reduced recovery and survival observed with simultaneous administration of stored platelets and amphotericin B in certain clinical conditions may result from increased P-selectin expression on the platelet surface that occurs during storage, being exacerbated by exposure to antibiotic. Novel approaches have been developed recently to improve the delivery of amphotericin B. The administration of liposomal amphotericin B preparations has an improved toxicity profile compared with the standard preparation. Other antifungals increasingly used as alternatives to amphotericin B for treatment of systemic fungal infection include ketoconazole and fluconazole.

Adhesion of unactivated platelets to PMN was increased in amphotericin B treated platelets probably because of the surface expression of P-selectin which mediates platelet–PMN adhesion via the P-selectin glycoprotein ligand-1 receptor on the PMN surface. Surface expression of P-selectin is increased in stored platelets. Exacerbation of this platelet storage lesion by amphotericin B could lead to increased binding of platelets to leukocytes which may be a potent mechanism in vivo for the clearance of platelets transfused concomitantly with amphotericin B from the circulation.

We used flow cytometry in conjunction with glycoprotein specific monoclonal antibodies to define further the abnormality in platelet function. In concurrence with previous studies, we observed thrombin modulation of the platelet surface GPIb-IX and GPIb-IIIa. These changes were not affected by treatment with amphotericin B. However, P-selectin, which is externalised from the internal α-granules and expressed on activated platelets, was expressed on the surface of unactivated platelets exposed to amphotericin B. In five-day stored platelets surface P-selectin

Amphotericin B induced abnormalities in human platelets